An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group.

Leung JM, Stanley T 3rd, Mathew J, Curling P, Barash P, Salmenpera M, Reves JG, Hollenberg M, Mangano DT

Anesthesia and analgesia1 Mar 1994Cited by 37 (Europe PMC)

PMID7818622DOI10.1213/00000539-199403000-00002PepBankPUB-07818622

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialSafety outcome
In coronary bypass patients, high-dose acadesine mildly increased plasma uric acid without clinical sequelae, unlike placebo and low-dose acadesine.
In plain wordsIn coronary bypass patients, only high-dose acadesine mildly increased uric acid, without clinical consequences.
Peptide
AICAR (acadesine)
Outcome
IncreasePlasma uric acid
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
High dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
Mean uric acid increase
1.6 mg/dL
high-dose acadesine
Reported uncertainty
0.2 mg/dL
type not stated
Source sentences
Summary
The administration of acadesine was safe: mild increases in plasma uric acid (a metabolite of acadesine) occurred only in patients receiving high doses (mean increase 1.6 +/- 0.2 mg/dL) and were without clinical sequelae.
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862201
02HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, low-dose acadesine showed similar prebypass ECG ischemia incidence to placebo.
In plain wordsIn coronary bypass patients, low-dose acadesine and placebo showed similar ECG signs of reduced heart blood flow before bypass.
Peptide
AICAR (acadesine)
Outcome
No significant changePrebypass ECG ischemia, low dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Low dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
Prebypass ECG ischemia
3%
low-dose acadesine
Prebypass ECG ischemia
0%
placebo
Source sentences
Summary
During prebypass, the incidence of ECG ischemia was similar in all three groups (0%, 3%, 3%, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862202
03HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, high-dose acadesine showed similar prebypass ECG ischemia incidence to placebo.
In plain wordsIn coronary bypass patients, high-dose acadesine and placebo showed similar ECG signs of reduced heart blood flow before bypass.
Peptide
AICAR (acadesine)
Outcome
No significant changePrebypass ECG ischemia, high dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
High dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
Prebypass ECG ischemia
3%
high-dose acadesine
Prebypass ECG ischemia
0%
placebo
Source sentences
Summary
During prebypass, the incidence of ECG ischemia was similar in all three groups (0%, 3%, 3%, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862203
04HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, low-dose acadesine numerically lowered TEE ischemia incidence versus placebo, without statistical significance.
In plain wordsIn coronary bypass patients, low-dose acadesine showed less heart ischemia on ultrasound than placebo, but the difference was not significant.
Peptide
AICAR (acadesine)
Outcome
No significant changeTEE ischemia incidence, low dose (period not stated)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Low dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
TEE ischemia
15%
low-dose acadesine
TEE ischemia
19%
placebo
P value
0.22 NA
between groups
Source sentences
Summary
The incidence of TEE ischemia was numerically lower in the two acadesine groups (high-dose = 6%, low-dose = 15%) than in the control group (19%), but this was not statistically significant (P = 0.22).
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862204
05HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, high-dose acadesine numerically lowered TEE ischemia incidence versus placebo, without statistical significance.
In plain wordsIn coronary bypass patients, high-dose acadesine showed less heart ischemia on ultrasound than placebo, but the difference was not significant.
Peptide
AICAR (acadesine)
Outcome
No significant changeTEE ischemia incidence, high dose (period not stated)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
High dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
TEE ischemia
6%
high-dose acadesine
TEE ischemia
19%
placebo
P value
0.22 NA
between groups
Source sentences
Summary
The incidence of TEE ischemia was numerically lower in the two acadesine groups (high-dose = 6%, low-dose = 15%) than in the control group (19%), but this was not statistically significant (P = 0.22).
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862205
06HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, low-dose acadesine did not significantly change postbypass ECG ischemia incidence versus placebo.
In plain wordsIn coronary bypass patients, low-dose acadesine did not significantly change ECG signs of heart ischemia after bypass compared with placebo.
Peptide
AICAR (acadesine)
Outcome
No significant changePostbypass ECG ischemia, low dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Low dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
Postbypass ECG ischemia
22%
low-dose acadesine
Postbypass ECG ischemia
18%
placebo
P value
0.42 NA
between groups
Source sentences
Summary
During postbypass, the incidence of ECG ischemia was 11% in the high-dose group, 22% in the low-dose group, and 18% in the control group (P = 0.42), and TEE ischemia was similar in incidence in all groups (placebo = 29%; low dose = 27%; high-dose = 24%) (P = 0.86).(ABSTRACT TRUNCATED AT 400 WORDS)
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862206
07HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, high-dose acadesine did not significantly change postbypass ECG ischemia incidence versus placebo.
In plain wordsIn coronary bypass patients, high-dose acadesine did not significantly change ECG signs of heart ischemia after bypass compared with placebo.
Peptide
AICAR (acadesine)
Outcome
No significant changePostbypass ECG ischemia, high dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
High dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
Postbypass ECG ischemia
11%
high-dose acadesine
Postbypass ECG ischemia
18%
placebo
P value
0.42 NA
between groups
Source sentences
Summary
During postbypass, the incidence of ECG ischemia was 11% in the high-dose group, 22% in the low-dose group, and 18% in the control group (P = 0.42), and TEE ischemia was similar in incidence in all groups (placebo = 29%; low dose = 27%; high-dose = 24%) (P = 0.86).(ABSTRACT TRUNCATED AT 400 WORDS)
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862207
08HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, low-dose acadesine showed similar postbypass TEE ischemia incidence to placebo.
In plain wordsIn coronary bypass patients, low-dose acadesine and placebo showed similar ultrasound signs of heart ischemia after bypass.
Peptide
AICAR (acadesine)
Outcome
No significant changePostbypass TEE ischemia, low dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Low dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
Postbypass TEE ischemia
27%
low-dose acadesine
Postbypass TEE ischemia
29%
placebo
P value
0.86 NA
between groups
Source sentences
Summary
During postbypass, the incidence of ECG ischemia was 11% in the high-dose group, 22% in the low-dose group, and 18% in the control group (P = 0.42), and TEE ischemia was similar in incidence in all groups (placebo = 29%; low dose = 27%; high-dose = 24%) (P = 0.86).(ABSTRACT TRUNCATED AT 400 WORDS)
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862208
09HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, high-dose acadesine showed similar postbypass TEE ischemia incidence to placebo.
In plain wordsIn coronary bypass patients, high-dose acadesine and placebo showed similar ultrasound signs of heart ischemia after bypass.
Peptide
AICAR (acadesine)
Outcome
No significant changePostbypass TEE ischemia, high dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
High dose, amount not stated · Intravenous infusion and cardioplegia · 7 hAs given in this study (human).
Measurements
Postbypass TEE ischemia
24%
high-dose acadesine
Postbypass TEE ischemia
29%
placebo
P value
0.86 NA
between groups
Source sentences
Summary
During postbypass, the incidence of ECG ischemia was 11% in the high-dose group, 22% in the low-dose group, and 18% in the control group (P = 0.42), and TEE ischemia was similar in incidence in all groups (placebo = 29%; low dose = 27%; high-dose = 24%) (P = 0.86).(ABSTRACT TRUNCATED AT 400 WORDS)
3 context sentences(design, population, supporting numbers)
Summary · context
Because patients undergoing coronary artery bypass graft (CABG) surgery are especially vulnerable to developing myocardial ischemia, we investigated whether perioperative use of this adenosine-regulating drug with potential anti-ischemic properties could modify the incidence and severity of perioper…
Summary · context
One hundred sixteen patients were randomized to receive one of three continuous intravenous dosing regimens (placebo [control] or one of two doses of acadesine [high- and low-dose infusion]) in double-blind fashion intraoperatively and in the early postoperative period (total infusion time was 7 h).
Summary · context
Multidose cold crystalloid cardioplegia (each containing either acadesine or placebo) was used for myocardial protection.
Report a problemFND-0781862209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.